Summit Street Capital Management LLC Makes New $44.45 Million Investment in Lantheus Holdings, Inc. $LNTH

Posted by on Aug 27th, 2026

Summit Street Capital Management LLC purchased a new position in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH – Free Report) in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 400,699 shares of the medical equipment provider’s stock, valued at approximately $44,454,000. Lantheus accounts for 6.2% of Summit Street Capital Management LLC’s holdings, making the stock its largest position.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Jupiter Topco LLC acquired a new position in Lantheus during the 2nd quarter worth about $575,628,000. ABS Investment Management LLC acquired a new position in Lantheus in the 2nd quarter valued at about $232,974,000. Hsbc Holdings PLC acquired a new position in Lantheus in the 2nd quarter valued at about $2,273,000. EFG International AG purchased a new stake in Lantheus during the second quarter worth about $100,000. Finally, Expect Equity LLC purchased a new stake in Lantheus during the second quarter worth about $3,558,000. Hedge funds and other institutional investors own 99.06% of the company’s stock.

Lantheus Trading Down 0.0%

LNTH opened at $100.82 on Thursday. The company has a quick ratio of 2.89, a current ratio of 3.06 and a debt-to-equity ratio of 0.43. Lantheus Holdings, Inc. has a 52 week low of $49.67 and a 52 week high of $111.86. The business’s 50 day moving average is $103.87 and its two-hundred day moving average is $91.26. The firm has a market cap of $6.58 billion, a price-to-earnings ratio of 24.35 and a beta of -0.03.

Lantheus (NASDAQ:LNTH – Get Free Report) last announced its earnings results on Thursday, August 6th. The medical equipment provider reported $1.55 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.30 by $0.25. Lantheus had a net margin of 17.69% and a return on equity of 28.10%. The business had revenue of $388.18 million for the quarter, compared to analyst estimates of $363.23 million. During the same period last year, the firm posted $1.57 earnings per share. The company’s revenue for the quarter was up 2.7% compared to the same quarter last year. On average, research analysts predict that Lantheus Holdings, Inc. will post 4.48 EPS for the current year.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on the stock. Weiss Ratings lowered shares of Lantheus from a “hold (c+)” rating to a “hold (c)” rating in a research note on Thursday, August 13th. Mizuho reduced their target price on shares of Lantheus from $120.00 to $115.00 and set an “outperform” rating on the stock in a report on Wednesday, July 29th. Truist Financial downgraded shares of Lantheus from a “buy” rating to a “hold” rating and dropped their price target for the stock from $125.00 to $102.50 in a research note on Monday, August 3rd. Wall Street Zen downgraded Lantheus from a “strong-buy” rating to a “buy” rating in a report on Saturday, May 9th. Finally, B. Riley Financial cut Lantheus from a “buy” rating to a “hold” rating in a research note on Monday, August 17th. Four analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the company. According to data from MarketBeat, Lantheus currently has an average rating of “Hold” and an average target price of $108.11.

Get Our Latest Stock Report on Lantheus

Lantheus Company Profile

(Free Report)

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.

Featured Stories

Want to see what other hedge funds are holding LNTH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Lantheus Holdings, Inc. (NASDAQ:LNTH – Free Report).

Institutional Ownership by Quarter for Lantheus (NASDAQ:LNTH)

Receive News & Ratings for Lantheus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus and related companies with MarketBeat.com's FREE daily email newsletter.